Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bungarus multicinctus-candidus Antivenom is a pharmaceutical drug used to treat envenoming caused by bites from the *Bungarus multicinctus* (many-banded krait) and *Bungarus candidus* (Malayan krait) snakes. These snake venoms are highly neurotoxic, primarily containing pre-synaptic phospholipase A2 (PLA2) β-bungarotoxins and post-synaptic α-bungarotoxins. These toxins disrupt neuromuscular transmission, leading to progressive neuromuscular paralysis and potentially fatal respiratory failure. The antivenom functions by neutralizing these specific toxins, thereby preventing or reversing their paralytic effects. Early administration of the antivenom is critical for optimal efficacy, as established neurotoxicity, particularly from β-bungarotoxins, can be resistant to treatment due to irreversible damage to nerve terminals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bungarus multicinctus-candidus Antivenom.